OverviewSuggest Edit

Exelixis is a genomics-based drug discovery company and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. It works on the development of anti-cancer therapies. Exelixis has several compounds in various stages of FDA approval including XL147 that targets phosphoinositide-3 kinase (PI3K); and XL765, which targets PI3K and mTOR, kinases in the PI3K signaling pathway; XL880 (foretinib). The Company also has various compounds in phase 1 clinical trials, including XL518 or GDC0973, a small molecule inhibitor of the MEK. Co-developed with Roche; XL228, which targets insulin-like growth factor type 1 receptor, an RTK in a range of human tumors; XL139 that targets Hedgehog; XL413, a small molecule inhibitor of the serine-threonine kinase CDC7; XL888, a synthetic inhibitor of HSP90, a chaperone protein that promotes the activity and stability of a range of regulatory proteins, including kinases. Its lead compound, XL184, has been approved for treatment of medullary thyroid cancer and is currently in a number of clinical trials for prostate, ovarian, brain, melanoma, breast, non-small cell lung, hepatocellular, kidney. During its trial for the treatment of medullary thyroid cancer, XL184 was designated orphan drug status by the FDA and given the generic name, cabozantinib. Cabozantinib is an inhibitor of the tyrosine kinases Met and VEGFR2, and has been shown to abrogate tumor growth, metastasis, and angiogenesis.


TypePublic
Founded1994
HQAlameda, CA, US
Websiteexelixis.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Dec 2019)617(+28%)
Job Openings106
Revenue (FY, 2018)$853.8 M(+89%)
Share Price (Jun 2021)$23
Cybersecurity ratingAMore

Key People/Management at Exelixis

Michael M. Morrissey

Michael M. Morrissey

President and Chief Executive Officer, Director
Stelios Papadopoulos

Stelios Papadopoulos

Chairman
Gisela M. Schwab

Gisela M. Schwab

President, Product Development and Medical Affairs and Chief Medical Officer
Charles Cohen

Charles Cohen

Director
Christopher J. Senner

Christopher J. Senner

Executive Vice President and Chief Financial Officer
Carl B. Feldbaum

Carl B. Feldbaum

Director
Show more

Exelixis Office Locations

Exelixis has an office in Alameda
Alameda, CA, US (HQ)
1851 Harbor Bay Pkwy
Show all (1)

Exelixis Financials and Metrics

Exelixis Revenue

Exelixis's revenue was reported to be $853.83 m in FY, 2018
USD

Revenue (Q1, 2021)

270.2m

Gross profit (Q1, 2021)

257.0m

Gross profit margin (Q1, 2021), %

95.1%

Net income (Q1, 2021)

1.6m

EBIT (Q1, 2021)

(4.6m)

Market capitalization (11-Jun-2021)

7.2b

Closing stock price (11-Jun-2021)

23.0

Cash (2-Apr-2021)

370.2m

EV

6.9b
Exelixis's current market capitalization is $7.2 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

289.6m47.5m31.3m25.1m37.2m452.5m853.8m

Revenue growth, %

48%

Cost of goods sold

1.1m2.0m3.9m15.1m26.3m

Gross profit

30.2m23.1m33.3m437.4m827.5m
Quarterly
USDQ3, 2011Q2, 2014Q3, 2014Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2021

Revenue

128.3m6.6m6.3m9.9m15.4m36.3m62.2m80.9m99.0m152.5m212.3m186.1m225.4m270.2m

Cost of goods sold

477.0k573.0k766.0k686.0k1.4m685.0k1.6m2.5m3.2m3.0m4.7m5.6m6.0m7.4m13.2m

Gross profit

6.1m5.7m8.4m14.7m34.7m59.7m77.7m96.0m147.9m206.7m180.1m218.0m257.0m

Gross profit Margin, %

93%91%86%96%96%96%96%97%97%97%97%97%95%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Cash

74.3m170.1m104.0m80.4m151.7m183.2m314.8m

Accounts Receivable

30.2m2.8m9.3m81.2m162.8m

Prepaid Expenses

4.4m6.1m8.8m15.0m

Inventories

5.1m3.5m3.3m6.7m9.8m
Quarterly
USDQ3, 2011Q2, 2014Q3, 2014Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2021

Cash

66.2m147.3m100.1m85.0m61.9m145.6m276.9m129.8m111.2m183.2m135.2m149.4m232.3m248.4m353.6m370.2m

Accounts Receivable

4.7m91.2m34.1m43.1m90.0m92.0m167.2m104.6m177.7m

Prepaid Expenses

17.1m7.1m6.3m4.4m8.0m6.9m10.3m12.3m46.3m

Inventories

3.0m3.9m2.6m2.6m2.1m2.5m2.8m3.3m3.3m5.4m5.8m7.6m8.4m10.4m24.8m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

75.7m(147.6m)(244.8m)(268.5m)(70.2m)154.2m690.1m

Depreciation and Amortization

6.8m5.7m3.1m2.4m1.0m1.2m4.9m

Inventories

1.0m1.5m(722.0k)(3.3m)(3.2m)

Accounts Payable

(5.6m)6.3m164.0k3.0m856.0k
Quarterly
USDQ3, 2011Q2, 2014Q3, 2014Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2021

Net Income

29.4m(73.4m)(62.6m)(35.2m)(43.4m)(47.6m)(61.3m)(37.0m)(105.3m)16.7m34.4m115.7m115.9m203.4m330.0m1.6m

Depreciation and Amortization

5.0m754.0k281.0k563.0k842.0k371.0k1.2m2.9m3.2m

Inventories

3.0m3.9m2.6m2.6m2.1m2.5m2.8m(676.0k)34.0k(2.1m)(2.5m)(906.0k)(1.7m)(3.8m)(2.1m)

Accounts Payable

(2.2m)4.6m3.4m1.3m3.4m2.3m5.7m5.4m18.8m(1.9m)472.0k(577.0k)(183.0k)(1.5m)(1.2m)138.0k
USDQ3, 2011

Financial Leverage

134.8 x
Show all financial metrics

Exelixis Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Exelixis Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Exelixis Online and Social Media Presence

Embed Graph

Exelixis News and Updates

Exelixis and Catalent Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag Bioconjugation Technology

Companies will partner to develop novel antibody-drug conjugates using Catalent’s SMARTag bioconjugation platform and monoclonal antibodies from Exelixis’ growing preclinical pipeline Agreement includes exclusive options on multiple targets over three-year term, with po…

Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma

Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma.read more

Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer

Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer.read more

Exelixis stock up more than 4% after FDA drug approval

Shares of Exelixis Inc. rose more than 4% in the extended session Monday after the Alameda, Calif., biotech company said the U.S. Food and Drug Administration has approved its Cabometix drug for patients with certain types of advanced liver cancer who have previously been treated with another drug.…

Kidney Cancer Treatment Drugs Market Analyzed by Business Growth| AstraZeneca, Aveo Pharmaceuticals, Bayer, Exelixis, Incyte, Merck, Roche, Pfizer, Bristol-Myers Squibb

Kidney Cancer Treatment Drugs Market Report aims to define, describe, and forecast on the basis of Market size, share, types, overview, top key vendors. This research report provides analysis and information according to market segments such as geography, technology and application. Posted via Indus…
Show more

Exelixis Blogs

Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence

Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence Content Import Fri, 06/18/2021 - 08:01 Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence 06/18/21 This release is a backfill from a Ne…

Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors

– Expansion cohorts to include patients with advanced kidney, prostate and bladder cancers – ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 14, 2021-- Exelixis, Inc. (Nasdaq: EXEL) today announced a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company (NYSE: BMY) for

Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

– New findings demonstrate the significant progression-free survival benefit seen in the intent-to-treat population was also consistent across subgroups – – Results from COSMIC-311 served as basis for Exelixis’ recent supplemental New Drug Application to U.S.

Exelixis Announces Positive Phase 2 Results for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021

– CABOMETYX in combination with OPDIVO demonstrated an objective response rate of 47.5% in a cohort of patients with certain histologies of advanced or metastatic nccRCC – – Data to be presented during the 2021 American Society of Clinical Oncology’s Annual Meeting – ALAMEDA, Calif.

Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Previously Untreated Advanced Renal Cell Carcinoma

– Patients treated with CABOMETYX in combination with OPDIVO had significantly longer total time without symptoms or toxicity – – Data to be presented during the 2021 American Society of Clinical Oncology’s Annual Meeting – ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 4, 2021-- Exelixis, Inc.

Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma

– Efficacy benefits with recently approved combination regimen observed regardless of baseline International Metastatic Renal Cell Carcinoma Database Consortium risk status, organ site of metastases or extent of tumor burden – – Data to be presented during the 2021 American Society of Clinical
Show more

Exelixis Frequently Asked Questions

  • When was Exelixis founded?

    Exelixis was founded in 1994.

  • Who are Exelixis key executives?

    Exelixis's key executives are Michael M. Morrissey, Stelios Papadopoulos and Gisela M. Schwab.

  • How many employees does Exelixis have?

    Exelixis has 617 employees.

  • What is Exelixis revenue?

    Latest Exelixis annual revenue is $853.8 m.

  • What is Exelixis revenue per employee?

    Latest Exelixis revenue per employee is $1.4 m.

  • Who are Exelixis competitors?

    Competitors of Exelixis include Taiho Pharmaceutical, BeyondSpring and PharmaEssentia.

  • Where is Exelixis headquarters?

    Exelixis headquarters is located at 1851 Harbor Bay Pkwy, Alameda.

  • Where are Exelixis offices?

    Exelixis has an office in Alameda.

  • How many offices does Exelixis have?

    Exelixis has 1 office.